Stay updated on Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.

Latest updates to the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page
- Check7 days agoChange DetectedFallopian tube cancer was added to the eligible conditions in the study description. The study now targets FRα-expressing tumors across ovarian, primary peritoneal, and fallopian tube cancers.SummaryDifference0.0%

- Check14 days agoChange DetectedRevision: v3.4.2 has been added to the site. The previous Revision: v3.4.1 entry and the outdated government operating-status notice were removed; no changes to the study content.SummaryDifference0.2%

- Check21 days agoChange DetectedNotice about government funding lapse and NIH operating status was added. The site revision indicator changed from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check28 days agoChange DetectedAdded a Show glossary option, a new Last Update Submitted that Met QC Criteria timestamp, and a No FEAR Act Data notice with Revision: v3.4.0. The prior Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4; a minor template/version update from v3.3.3 to v3.3.4 with no user-facing changes to study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedLocations section updated to include new site entries across the US and international regions; earlier location groupings were removed.SummaryDifference2%

Stay in the know with updates to Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.